Details

Autor(en) / Beteiligte

• Tebruegge, M
• Buonsenso, D
• Brinkmann, F
• Noguera-Julian, A
• Pavić, I
• Arbore, A Sorete
• Vančíková, Z
• Velizarova, S
• Welch, S B
• Ritz, N

Titel

European shortage of purified protein derivative and its impact on tuberculosis screening practices

Ist Teil von

• The international journal of tuberculosis and lung disease, 2016-10, Vol.20 (10), p.1293

Ort / Verlag

France

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• In June 2014, we became aware that shortages of purified protein derivative (PPD), the test substance used for the tuberculin skin test (TST), had occurred in several European health care institutions providing care for children with tuberculosis (TB). To establish the extent of the shortage, a survey was performed. Survey conducted over a 1-month period (June-July 2014) among members of the Paediatric Tuberculosis Network European Trials Group (ptbnet). Thirty-five physicians from 23 European countries contributed data. The most commonly used PPD product was RT23 (Statens Serum Institut; n = 22, 63%). Twenty-one (60%) participants reported that their institution was experiencing a PPD shortage. The majority (n = 17, 81%) of those reporting a shortage were using RT23. Thirteen (37%) participants reported changes in screening practices resulting from the shortage, including sourcing PPD from alternative manufacturers, restricting remaining supplies to patients at greatest risk or replacing TST by an interferon-gamma release assay. The data show that a PPD shortage occurred in 2014, affecting multiple European countries. The shortage resulted in changes in TB screening capabilities and practices, potentially compromising both patient care as well as public health efforts. Appropriate actions to prevent future PPD shortages should be explored urgently by public health agencies and key stakeholders.